Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients-Reference-Cited by-同舟云学术

Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

Published:2016-10-08 Issue:7 Volume:52 Page:788-799
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Iborra Marisa^ORCID, ,Pérez-Gisbert Javier,Bosca-Watts Marta Maia,López-García Alicia,García-Sánchez Valle,López-Sanromán Antonio,Hinojosa Esther,Márquez Lucía,García-López Santiago,Chaparro María,Aceituno Montserrat,Calafat Margalida,Guardiola Jordi,Belloc Blanca,Ber Yolanda,Bujanda Luis,Beltrán Belén,Rodríguez-Gutiérrez Cristina,Barrio Jesús,Cabriada José Luis,Rivero Montserrat,Camargo Raquel,van Domselaar Manuel,Villoria Albert,Schuterman Hugo Salata,Hervás David,Nos Pilar

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/article/10.1007/s00535-016-1274-1/fulltext.html

Reference34 articles.

1. Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27.

2. Seo GS, Chae SC. Biological therapy for ulcerative colitis: an update. World J Gastroenterol. 2014;20:13234–8.

3. Tursi A, Penna A. Onset of ulcerative colitis under treatment with adalimumab. Am J Gastroenterol. 2008;103:2410–2.

4. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol. 2009;15:3814–6.

5. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–32.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Course of Bio Naive Ulcerative Colitis Patients Five Years After Initiation of Adalimumab in a Nationwide Cohort;Crohn's & Colitis 360;2024-07-01

2. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis;Pharmacological Research;2024-04

3. Predictive biomarkers for anti-TNF alpha therapy in IBD patients;Journal of Translational Medicine;2024-03-16

4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry;Therapeutic Advances in Gastroenterology;2024-01

5. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease;Journal of Clinical Medicine;2023-10-29